Αποτελέσματα Αναζήτησης
In high-risk patients, systemic chemotherapy is generally recommended. There are several standard chemotherapy options, typically containing both an anthracycline and a taxane. In the United States, doxorubicin and cyclophosphamide for 4 cycles followed by paclitaxel for 4 cycles (AC-T) is a common regimen.
- Figure 2
Breast cancer treatment is multidisciplinary. The majority...
- Figure 2
8 Οκτ 2014 · Based on these studies, TCH, AC-TH, and sequential anthracycline–trastuzumab are standard adjuvant therapy options in this population. Adjuvant chemotherapy is recommended even for small node-negative HER2-breast cancer, but the threshold for treatment is disputed.
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
17 Αυγ 2015 · The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes.
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
Cost: ~ $530 per cycle "How this cost is calculated" The cost displayed on the protocol is intended as rudimentary guide only for the Australian context. The cost includes anti-cancer drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.
We aim to evaluate the non-inferiority of an anthracycline-free or short-term regimen to the standard anthracycline-based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods. It is a prospective, open-label, phase 3, randomized non-inferiority trial from June 1, 2010 to June 1, 2017.
